Tenofovir Disoproxil Fumarate (TDF) is an orally administered prodrug of tenofovir. Tenofovir is similar to Adefovir, which is used for the treatment of HIV and chronic hepatitis B virus infections.
Gilead Sciences Inc. originally developed it under the brand name Viread, tenofovir disoproxil fumarate, or TDF. Gilead sells five different TDF brand name drugs in the United States, and the drug also comes in generic form.
The U.S. FDA on October 26, 2001, approved Tenofovir disoproxil for the treatment of HIV, and on August 11, 2008, for the treatment of chronic hepatitis B.
Gilead Sciences, Inc.'s Truvada for the treatment of HIV-1 infection in adults was approved by the FDA on August 2, 2004.
The FDA approved Truvada for reducing the risk of sexually-acquired HIV infection in adults on July 16th, 2012.
The FDA expands approval for reducing the risk of HIV infection in adolescents on May 15, 2018.
In 2001, the first documented instance of kidney toxicity over the usage of TDF occurred in the United States, which was the same year the drug hit the market. The instance was reported by Willem D.F. Venter and the coauthors of a 2018 study in Southern African Journal of HIV Medicine. The patient suffered acute kidney injury (AKI), Fanconi syndrome, and nephrogenic diabetes insipidus.
AIDS Health Foundation (AHF), the largest global AIDS organization, sued Gilead in 2016, following which the TDF litigation began. The company was accused of manipulating the patent system by withholding from patients a more potent, less toxic drug called TAF.
Severe side effects:
High blood lactate